Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | REN | P00797 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931129 | 0.89 | ALDH1A1 (0.66) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL2902849 | 0.87 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8668663 | 0.87 | NPC1 (0.53) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8668061 | 0.87 | NPC1 (0.53) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL4089947 | 0.86 | NPC1 (0.56) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL27498819 | 0.86 | NPC1 (0.60) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8670024 | 0.85 | RAB9A (0.51) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL2798062 | 0.84 | REN (0.61) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL28918715 | 0.84 | NPC1 (0.54) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL5460753 | 0.84 | ALDH1A1 (0.54) | NPC1RAB9AKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118979385-A | Clothes ironing and sizing aerosol and preparation method thereof | 广东卫斯理化工科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118909315-A | Double-degradation food packaging film and preparation method thereof | 郑州市彦峰塑料包装有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118406371-A | Flame-retardant material for circuit board box and preparation method thereof | 中山市龙正塑料五金制品有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117966518-B | Pressure-resistant anti-deformation corrugated board and preparation process thereof | 东莞市益和纸制品有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-117966518-A | Pressure-resistant anti-deformation corrugated board and preparation process thereof | 东莞市益和纸制品有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112142814-B | Tauroursodeoxycholic acid derivative, and pharmaceutical composition and preparation comprising same | 江苏吉贝尔药业股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-112142814-A | Tauroursodeoxycholic acid derivative, and pharmaceutical composition and preparation comprising same | 江苏吉贝尔药业股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-6908999-B2 | Hydrolysis of N,N-disubstituted (2-(4-(alpha-phenyl-p-chloro-benzyl)piperazin-1-yl)ethoxy)acetamide, to form cetirizine and salts, used as antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2005-06-21 | — | — | US | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | disclosed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | disclosed |
| EP-1233954-A1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040211-A1 | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-06-07 | — | — | WO | disclosed |
| EP-0226730-B1 | Compounds and assay for tricyclic antidepressants | ABBOTT LAB (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0226730-A2 | Compounds and assay for tricyclic antidepressants | ABBOTT LABORATORIES (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | NPC1 2167/4885RAB9A 4521/4885KMT2A 906/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | NPC1 608/4885RAB9A 3011/4885KMT2A 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.